| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
In this study, I examined the role of Vasohibin-2 (VASH2) in rhabdomyosarcoma. Functional analysis of human alveolar rhabdomyosarcoma cells revealed that VASH2 was required for cell attachment to extracellular matrix, tumor formation ability, and tumor immunity. I then examined the properties of VASH2 protein and found that the interaction between VASH2 and small vasohibin binding protein (SVBP) enhanced the stability of VASH2 protein and provided the binding ability of VASH2-SVBP complex to phosphatidylinositol. I further isolated and identified novel proteins associated with VASH2 and/or SVBP.
|
